查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2137824

活菌產品 (LBP) 和微生物組 CDMO 服務市場：全球市場預測，2026-2032 年

Live Biotherapeutic Products & Microbiome CDMO Service Market - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，活菌產品 (LBP) 和微生物組 CDMO 服務市場將成長至 49.8 億美元，複合年成長率為 12.33%。

主要市場統計數據
基準年 2025 22億美元
預計年份：2026年 24.5億美元
預測年份 2032 49.8億美元
複合年成長率 (%) 12.33%

活菌產品 (LBP) 和微生物組 CDMO 服務：概述

活微生物產品（LBPs，不包括傳統疫苗）是指用於預防、治療或控制疾病的微生物製劑。微生物組契約開發和生產（CDMO）服務支援菌株選擇、細胞庫建構、製程開發、分析測試、製劑配製、臨床生產和商業化生產等活動。隨著研究人員不斷尋求更精確地影響微生物群落及其與人類健康相互作用的方法，該領域持續發展。由於產品可能包含多種菌株，需要受控的氧氣條件，並且需要對活性、可識別性、純度和效力等特性進行嚴格控制，因此開發仍需要先進的技術。

一場變革性的變革，重塑了液態鉛基聚合物的開發與製造。

益生菌的研發格局正從經驗式開發轉向基於機制的產品設計、明確的菌叢組合、基因改造菌株以及患者特異性微生物組分析。監管機構和研發人員越來越重視產品特性、可重複的生產流程、污染控制以及具有臨床意義的功效測試。生產模式也在整合平台發展，這些平台結合了厭氧加工、先進定序、冷凍保存、專業填充和表面處理工程以及經過驗證的冷鏈物流。這些變化提升了能夠提供早期技術風險評估並整合微生物學、製程工程、分析、品質系統和臨床供應鏈執行的研發合作夥伴的價值。

人工智慧（AI）將加速藥物發現、表徵和品管。

人工智慧 (AI) 可透過分析元基因組、代謝組學、轉錄組學、臨床和生產資料集來識別微生物特徵，並確定候選菌株和菌群的優先級，從而幫助該領域的研究。機器學習工具可以幫助預測生長行為、培養基性能和穩定性以及製程偏差，而電腦視覺和多變量監測則可以增強環境和進程內品管。然而，人工智慧的輸出需要經過整理的資料集、檢驗的工作流程、可解釋的決策標準以及手動監督。資料協調、病患隱私、模型漂移和法規核准仍然是重要的阻礙因素，尤其是在演算法影響產品選擇、出貨檢測或臨床決策時。

區域洞察：六大區域的能力與監管環境

北美擁有完善的生物製藥基礎設施、活躍的轉化研究以及豐富的複雜臨床生產經驗，但與監管機構的合作對於確定產品分類和證據要求仍然至關重要。歐洲將強大的微生物組研究與完善的品管和先進的治療生態系統相結合，但需要協調國家層面的流程和歐盟的要求。亞太地區的特點是生物程序能力不斷提升、擁有龐大的研究群體以及日益活躍的臨床開發活動，但各地區的成熟度有所不同。拉丁美洲正在發展研究、臨床和生產網路，但由於其獨特的厭氧環境，可能面臨基礎設施和物流方面的限制。中東正在投資生物技術和醫療保健的現代化，但獲得專業生產和監管專業知識的機會在各地區仍然存在差異。非洲擁有龐大的微生物組研究機會和尚未滿足的需求，但也面臨基礎設施、資金籌措、冷鏈連續性和專業品管系統的限制。

集團洞察：主要多邊組織和經濟區域對實施的影響

東南亞國協正在推動生物技術領域的合作，並加強區域醫療衛生體系建設，但監管成熟度和生產基礎設施的差異正在影響跨境發展。金磚國家在科學、臨床實踐和生物製造方面擁有豐富的資源，但標準協調和技術取得保障仍然是關鍵挑戰。歐盟透過通用框架支持研發合作和市場進入，同時對品質、安全和資料完整性提出嚴格要求。七國集團成員國擁有先進的藥物發現、臨床實踐、監管和生產能力，政策協調正在影響技術轉移和供應韌性。海灣合作理事會成員國正透過投資醫療保健和經濟多元化來建立生命科學能力，從而創造專業夥伴關係機會。北約成員國擁有眾多先進的生物醫學生態系統，但國防相關優先事項與商業性生命科學產品開發有所不同，不應被視為單一的監管市場。

國家概況：研發、監理與生產環境的差異

美國擁有先進的生物醫學研究、創投活動、臨床基礎設施和專業製造能力，但需要儘早考慮監管分類和證據策略。加拿大在微生物組研究和公共部門科學研究能力方面具有優勢，但可能需要建立合作夥伴關係才能擴大專業化生產的規模。英國擁有卓越的生命科學和臨床研究資源，脫歐後的監管調整對發展計畫至關重要。法國、德國、義大利和西班牙在歐盟框架內擁有先進的學術、醫院、製藥和生物程序能力，但各國的實施和採購條件各不相同。澳洲將強大的醫學研究與地域分散的供應鏈結合。中國和日本在研究、醫療保健和製造方面擁有相當的實力，但開發公司需要滿足當地的監管、數據和品質要求。韓國正在拓展其在生物製藥和臨床製造方面的專業知識。印度擁有廣泛的製藥和臨床能力，但微生物組的專業流程管理和一致性仍然是重要的實施考量。巴西和墨西哥在拉丁美洲提供至關重要的研發和臨床平台，基礎設施、監管協調和物流將決定專案的可行性。俄羅斯保持其科學研究和工業實力，但制裁、貿易限制和國際合作的限制可能會影響其採購、研發以及進入全球臨床網路的機會。

建構可靠的LBP平台的領導優先事項

領導者應在選擇菌株前明確目標產品特性和作用機制，然後制定將分析方法與臨床終點聯繫起來的開發計劃。應儘早投資於菌株真實性驗證、基因組表徵、細胞庫建構、厭氧製程控制、污染預防和穩定性測試。對培養基、一次性組件、專用設備和冷鏈服務實施基於風險的供應商合格，並制定關鍵投入品的緊急時應對計畫。選擇CDMO合作夥伴時，不僅應考慮其整體生產能力，還應考慮其處理活細胞、氧敏感產品、多菌株產品或其他複雜生物製藥的經驗。在實施人工智慧之前，應建立資料標準和管治，並確保所有模型均已針對其預期用途檢驗。在做出關鍵的臨床供應決策之前，應整合監管諮詢、技術轉移計劃、可比性方案和出庫檢驗策略。

調查方法執行摘要

本概要運用定性且基於證據的框架，對已定義的活體生物製藥（LBP）和微生物組契約研發生產（CDMO）服務領域進行分析。它整合了成熟的科學和生產原則，涵蓋產品表徵、菌株和菌群開發、厭氧處理、分析控制、製劑、穩定性、監管策略、臨床供應和物流。區域、集團和國家層面的具體考量著重於研究能力、生物製藥基礎設施、監管協調、醫療保健系統和供應鏈格局的顯著差異。本概要未使用任何市場估算、預測、市佔率、預估或公司特定聲明。由於能力和政策會隨時間變化，專案決策應根據當前的關鍵監管指南、同行評審的研究、臨床試驗記錄和經審核的現場文件進行檢驗。

結論：嚴格執行是LBP和微生物組成功的關鍵。

LBP 和微生物組 CDMO 服務正朝著更高的目標發展，即提供更清晰的產品、更強力的機制證據和可重複的生產流程。核心挑戰並非只是藥物發現，而是將複雜的微生物生物學轉化為穩定、可測量、可擴展且臨床可靠的產品。整合微生物學、分析、程式工程、品管、法規策略、數位化管治和供應鏈韌性的機構將更有能力管理技術和營運風險。夥伴關係和設施選擇應根據區域和國家的具體情況進行調整，但從最初的菌株篩選到臨床和商業性供應，嚴格的驗證至關重要。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 活菌產品 (LBP) 與微生物組 CDMO 服務市場：依服務類型分類

  • 分析服務
    • 生物分析測試
    • 微生物檢測
  • 臨床開發
    • I期臨床試驗
    • 二期臨床試驗
    • III期臨床試驗
  • 商業生產
    • 下游加工
    • 填充和精加工
    • 上游工程

第8章：活菌產品 (LBP) 與微生物組 CDMO 服務市場：依技術平台分類

  • 封裝
    • 微膠囊化
    • 奈米封裝
  • 發酵
    • 有氧發酵
    • 厭氧發酵
  • 基因工程
    • CRISPR
    • 質體工程
  • 冷凍乾燥
    • 大批量冷凍乾燥
    • 管瓶凍乾

第9章：活菌產品 (LBP) 和微生物組 CDMO 服務市場：依治療領域分類

  • 消化系統疾病
  • 感染疾病
    • 細菌感染疾病
    • 病毒感染疾病
  • 代謝性疾病
  • 腫瘤學

第10章：活菌產品 (LBP) 和微生物組 CDMO 服務市場：依給藥途徑分類

  • 注射藥物
    • 靜脈
    • 皮下
  • 口服
    • 膠囊
    • 藥片
  • 直腸
  • 外用

第11章 活菌產品 (LBP) 與微生物組 CDMO 服務市場：依專案階段分類

  • 商業的
  • 第一階段
  • 第二階段
  • 第三階段
  • 臨床前階段

第12章 活菌產品 (LBP) 與微生物組 CDMO 服務市場：依最終用戶分類

  • 受託研究機構
  • 製藥公司
  • 研究機構

第13章：活菌產品 (LBP) 和微生物組 CDMO 服務市場：按地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第14章 活菌產品 (LBP) 與微生物組 CDMO 服務市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章：活菌產品 (LBP) 和微生物組 CDMO 服務市場：按國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 2025年市佔率分析
  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第17章：公司簡介

  • 4D Pharma plc
  • AOBiome, Inc.
  • Assembly Biosciences, Inc.
  • Azitra, Inc.
  • Bacthera, SA
  • Biocodex, SA
  • BiomeBank Pty Ltd
  • Biose Industrie SA
  • BJP Laboratories, Inc.
  • Cerbios-Pharma SA
  • Chr. Hansen Holding A/S
  • Eligo Bioscience, Inc.
  • EnteroBiotix Ltd
  • Enterome, SA
  • Exeliom Biosciences, SA
  • Finch Therapeutics Group, Inc.
  • Ginkgo Bioworks, Inc.
  • Infant Bacterial Therapeutics IBT AB
  • Inpac Probiotics, Inc.
  • List Biological Laboratories, Inc.
  • Lonza Group Ltd
  • MaaT Pharma, SA
  • Microbiotica Ltd
  • MRM Health NV
  • NIZO BV
  • Quay Pharmaceuticals Ltd
  • Rebiotix, Inc.
  • Seres Therapeutics, Inc.
  • Synlogic, Inc.
  • Vedanta Biosciences, Inc.
  • WACKER Chemie AG

第18章 主要專家

Product Code: MRR-961F26FD8352

The Live Biotherapeutic Products & Microbiome CDMO Service Market is projected to grow by USD 4.98 billion at a CAGR of 12.33% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 2.20 billion
Estimated Year [2026] USD 2.45 billion
Forecast Year [2032] USD 4.98 billion
CAGR (%) 12.33%

Live Biotherapeutic Products and Microbiome CDMO Services: Executive Overview

Live biotherapeutic products (LBPs) are defined microbial preparations intended to prevent, treat, or manage disease, excluding conventional vaccines. Microbiome contract development and manufacturing organization (CDMO) services support activities such as strain selection, cell banking, process development, analytical testing, formulation, clinical manufacturing, and commercial-scale production. The field is advancing as researchers seek more precise ways to influence microbial communities and their interactions with human health. Development remains technically demanding because products may contain multiple strains, require controlled oxygen conditions, and depend on tightly managed viability, identity, purity, and potency attributes.

Transformative Shifts Reshaping LBP Development and Manufacturing

The landscape is shifting from empirical probiotic development toward mechanism-led product design, defined consortia, engineered strains, and patient-specific microbiome profiling. Regulators and developers are placing greater emphasis on product characterization, reproducible manufacturing, contamination control, and clinically relevant potency assays. Manufacturing models are also evolving toward integrated platforms that combine anaerobic processing, advanced sequencing, cryopreservation, specialized fill-finish, and validated cold-chain logistics. These changes increase the value of early technical risk assessment and of development partners able to connect microbiology, process engineering, analytics, quality systems, and clinical supply execution.

Artificial Intelligence Accelerates Discovery, Characterization, and Quality Control

Artificial intelligence can support the field by analyzing metagenomic, metabolomic, transcriptomic, clinical, and manufacturing datasets to identify microbial signatures and prioritize candidate strains or consortia. Machine-learning tools may also help predict growth behavior, media performance, stability, and process deviations, while computer vision and multivariate monitoring can strengthen environmental and in-process quality control. However, AI outputs require curated datasets, validated workflows, interpretable decision criteria, and human oversight. Data harmonization, patient privacy, model drift, and regulatory acceptance remain important constraints, particularly when algorithms influence product selection, release testing, or clinical decisions.

Regional Insights: Capabilities and Regulatory Conditions Across Six Geographies

North America benefits from established biopharmaceutical infrastructure, active translational research, and experience with complex clinical manufacturing, while regulatory engagement remains central to defining product classification and evidence requirements. Europe combines strong microbiome research with sophisticated quality and advanced-therapy ecosystems, although country-level processes and European Union requirements must be coordinated. Asia-Pacific offers expanding bioprocessing capacity, major research communities, and increasing clinical-development activity, with capability maturity varying by jurisdiction. Latin America is developing research, clinical, and manufacturing networks but may face limits in specialized anaerobic infrastructure and logistics. The Middle East is investing in biotechnology and healthcare modernization, while access to specialized production and regulatory expertise remains uneven. Africa presents important microbiome research opportunities and unmet clinical needs, alongside constraints involving infrastructure, funding, cold-chain continuity, and specialized quality systems.

Group Insights: How Major Multilateral and Economic Blocs Shape Adoption

ASEAN countries are strengthening biotechnology collaboration and regional healthcare capacity, but differences in regulatory maturity and manufacturing infrastructure affect cross-border development. BRICS economies provide substantial scientific, clinical, and biomanufacturing resources, while alignment of standards and technology access remains important. The European Union supports coordinated research and market access through shared frameworks, alongside demanding requirements for quality, safety, and data integrity. G7 members contribute advanced discovery, clinical, regulatory, and manufacturing capabilities, with policy coordination influencing technology transfer and supply resilience. GCC states are building life-science capacity through healthcare investment and economic diversification, creating opportunities for specialized partnerships. NATO members collectively include many advanced biomedical ecosystems, although defense-related priorities are distinct from commercial LBP development and should not be treated as a single regulatory market.

Country Insights: Differentiated Research, Regulatory, and Manufacturing Environments

The United States combines deep biomedical research, venture activity, clinical infrastructure, and specialized manufacturing, with regulatory classification and evidence strategy requiring early attention. Canada offers strong microbiome research and public-sector scientific capacity, while scaling specialized production can require coordinated partnerships. The United Kingdom has prominent life-science and clinical research assets, with post-EU regulatory coordination relevant to development planning. France, Germany, Italy, and Spain contribute advanced academic, hospital, pharmaceutical, and bioprocessing capabilities within the broader European Union framework, though national implementation and procurement conditions differ. Australia combines strong medical research with geographically dispersed supply chains. China and Japan have substantial research, healthcare, and manufacturing capabilities, but developers must address local regulatory, data, and quality requirements. South Korea is expanding biopharmaceutical and clinical-manufacturing expertise. India offers extensive pharmaceutical and clinical capabilities, while specialized microbiome process controls and consistency remain key execution considerations. Brazil and Mexico provide important Latin American research and clinical platforms, with infrastructure, regulatory coordination, and logistics shaping project feasibility. Russia retains scientific and industrial capabilities, although sanctions, trade restrictions, and international collaboration constraints may affect sourcing, development, and access to global clinical networks.

Action Priorities for Leaders Building Reliable LBP Platforms

Leaders should define the target product profile and mechanism of action before selecting strains, then establish a development plan linking analytical methods to clinical endpoints. Invest early in strain authentication, genomic characterization, cell banking, anaerobic process control, contamination prevention, and stability studies. Use risk-based supplier qualification for media, single-use components, specialized equipment, and cold-chain services, with contingency plans for critical inputs. Select CDMO partners based on demonstrated handling of live, oxygen-sensitive, multi-strain, or otherwise complex biological products rather than general capacity alone. Establish data standards and governance before introducing AI, and ensure every model is validated for its intended use. Regulatory consultations, technology-transfer planning, comparability protocols, and release-testing strategies should be integrated before pivotal clinical supply decisions.

Research Methodology for the Executive Summary

This summary applies a qualitative, evidence-led framework to the defined LBP and microbiome CDMO service domain. It synthesizes established scientific and manufacturing principles covering product characterization, strain and consortium development, anaerobic processing, analytical control, formulation, stability, regulatory strategy, clinical supply, and logistics. Regional, group, and country discussion is structured around observable differences in research capacity, biopharmaceutical infrastructure, regulatory coordination, healthcare systems, and supply-chain conditions. No market estimates, market shares, forecasts, or company-specific claims are used. Because capabilities and policies change over time, project decisions should be verified against current primary regulatory guidance, peer-reviewed research, clinical-trial records, and audited facility documentation.

Conclusion: Execution Discipline Will Determine LBP and Microbiome Success

LBPs and microbiome CDMO services are progressing toward more defined products, stronger mechanistic evidence, and higher expectations for reproducible manufacturing. The central challenge is not discovery alone; it is translating complex microbial biology into a stable, measurable, scalable, and clinically credible product. Organizations that integrate microbiology, analytics, process engineering, quality, regulatory strategy, digital governance, and supply resilience will be better positioned to manage technical and operational risk. Regional and country conditions should guide partnership and facility choices, while disciplined validation remains essential from early strain selection through clinical and commercial supply.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. New Revenue Opportunities
  • 3.4. Next-Generation Business Models
  • 3.5. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Live Biotherapeutic Products & Microbiome CDMO Service Market, by Service Type

  • 7.1. Introduction
  • 7.2. Analytical Services
    • 7.2.1. Bioanalytical Testing
    • 7.2.2. Microbiological Testing
  • 7.3. Clinical Development
    • 7.3.1. Phase I Trials
    • 7.3.2. Phase II Trials
    • 7.3.3. Phase III Trials
  • 7.4. Commercial Manufacturing
    • 7.4.1. Downstream Processing
    • 7.4.2. Fill Finish
    • 7.4.3. Upstream Processing

8. Live Biotherapeutic Products & Microbiome CDMO Service Market, by Technology Platform

  • 8.1. Introduction
  • 8.2. Encapsulation
    • 8.2.1. Microencapsulation
    • 8.2.2. Nanoencapsulation
  • 8.3. Fermentation
    • 8.3.1. Aerobic Fermentation
    • 8.3.2. Anaerobic Fermentation
  • 8.4. Genetic Engineering
    • 8.4.1. CRISPR
    • 8.4.2. Plasmid Engineering
  • 8.5. Lyophilization
    • 8.5.1. Bulk Lyophilization
    • 8.5.2. Vial Lyophilization

9. Live Biotherapeutic Products & Microbiome CDMO Service Market, by Therapeutic Area

  • 9.1. Introduction
  • 9.2. Gastrointestinal Disorders
  • 9.3. Infectious Diseases
    • 9.3.1. Bacterial Infections
    • 9.3.2. Viral Infections
  • 9.4. Metabolic Disorders
  • 9.5. Oncology

10. Live Biotherapeutic Products & Microbiome CDMO Service Market, by Route Of Administration

  • 10.1. Introduction
  • 10.2. Injectable
    • 10.2.1. Intravenous
    • 10.2.2. Subcutaneous
  • 10.3. Oral
    • 10.3.1. Capsule
    • 10.3.2. Tablet
  • 10.4. Rectal
  • 10.5. Topical

11. Live Biotherapeutic Products & Microbiome CDMO Service Market, by Project Phase

  • 11.1. Introduction
  • 11.2. Commercial
  • 11.3. Phase I
  • 11.4. Phase II
  • 11.5. Phase III
  • 11.6. Preclinical

12. Live Biotherapeutic Products & Microbiome CDMO Service Market, by End User

  • 12.1. Introduction
  • 12.2. Contract Research Organizations
  • 12.3. Pharmaceutical Companies
  • 12.4. Research Institutes

13. Live Biotherapeutic Products & Microbiome CDMO Service Market, by Region

  • 13.1. Introduction
  • 13.2. Asia-Pacific
  • 13.3. North America
  • 13.4. Latin America
  • 13.5. Europe
  • 13.6. Middle East
  • 13.7. Africa

14. Live Biotherapeutic Products & Microbiome CDMO Service Market, by Group

  • 14.1. Introduction
  • 14.2. ASEAN
  • 14.3. GCC
  • 14.4. European Union
  • 14.5. BRICS
  • 14.6. G7
  • 14.7. NATO

15. Live Biotherapeutic Products & Microbiome CDMO Service Market, by Country

  • 15.1. Introduction
  • 15.2. United States
  • 15.3. Canada
  • 15.4. Mexico
  • 15.5. Brazil
  • 15.6. United Kingdom
  • 15.7. Germany
  • 15.8. France
  • 15.9. Russia
  • 15.10. Italy
  • 15.11. Spain
  • 15.12. China
  • 15.13. India
  • 15.14. Japan
  • 15.15. Australia
  • 15.16. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2025
  • 16.2. Market Concentration Analysis, 2025
    • 16.2.1. Concentration Ratio (CR)
    • 16.2.2. Herfindahl Hirschman Index (HHI)
  • 16.3. Recent Developments & Impact Analysis, 2025
  • 16.4. Product Portfolio Analysis, 2025
  • 16.5. Benchmarking Analysis, 2025

17. Company Profiles

  • 17.1. 4D Pharma plc
  • 17.2. AOBiome, Inc.
  • 17.3. Assembly Biosciences, Inc.
  • 17.4. Azitra, Inc.
  • 17.5. Bacthera, S.A.
  • 17.6. Biocodex, S.A.
  • 17.7. BiomeBank Pty Ltd
  • 17.8. Biose Industrie S.A.
  • 17.9. BJP Laboratories, Inc.
  • 17.10. Cerbios-Pharma SA
  • 17.11. Chr. Hansen Holding A/S
  • 17.12. Eligo Bioscience, Inc.
  • 17.13. EnteroBiotix Ltd
  • 17.14. Enterome, S.A.
  • 17.15. Exeliom Biosciences, S.A.
  • 17.16. Finch Therapeutics Group, Inc.
  • 17.17. Ginkgo Bioworks, Inc.
  • 17.18. Infant Bacterial Therapeutics IBT AB
  • 17.19. Inpac Probiotics, Inc.
  • 17.20. List Biological Laboratories, Inc.
  • 17.21. Lonza Group Ltd
  • 17.22. MaaT Pharma, S.A.
  • 17.23. Microbiotica Ltd
  • 17.24. MRM Health NV
  • 17.25. NIZO B.V.
  • 17.26. Quay Pharmaceuticals Ltd
  • 17.27. Rebiotix, Inc.
  • 17.28. Seres Therapeutics, Inc.
  • 17.29. Synlogic, Inc.
  • 17.30. Vedanta Biosciences, Inc.
  • 17.31. WACKER Chemie AG

18. Key Experts

LIST OF FIGURES

  • FIGURE 1. Global Live Biotherapeutic Products & Microbiome CDMO Service Market, Years Considered for the Study
  • FIGURE 2. Global Live Biotherapeutic Products & Microbiome CDMO Service Market, Research Design
  • FIGURE 3. Global Live Biotherapeutic Products & Microbiome CDMO Service Market, Research Framework
  • FIGURE 4. Global Live Biotherapeutic Products & Microbiome CDMO Service Market, Data Triangulation
  • FIGURE 5. Global Live Biotherapeutic Products & Microbiome CDMO Service Market Size, 2017-2032 (USD Million)
  • FIGURE 6. Global Live Biotherapeutic Products & Microbiome CDMO Service Market Size, by Service Type, 2025 vs 2032 (%)
  • FIGURE 7. Global Live Biotherapeutic Products & Microbiome CDMO Service Market Size, by Service Type, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 8. Global Live Biotherapeutic Products & Microbiome CDMO Service Market Size, by Technology Platform, 2025 vs 2032 (%)
  • FIGURE 9. Global Live Biotherapeutic Products & Microbiome CDMO Service Market Size, by Technology Platform, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 10. Global Live Biotherapeutic Products & Microbiome CDMO Service Market Size, by Therapeutic Area, 2025 vs 2032 (%)
  • FIGURE 11. Global Live Biotherapeutic Products & Microbiome CDMO Service Market Size, by Therapeutic Area, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 12. Global Live Biotherapeutic Products & Microbiome CDMO Service Market Size, by Route Of Administration, 2025 vs 2032 (%)
  • FIGURE 13. Global Live Biotherapeutic Products & Microbiome CDMO Service Market Size, by Route Of Administration, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 14. Global Live Biotherapeutic Products & Microbiome CDMO Service Market Size, by Project Phase, 2025 vs 2032 (%)
  • FIGURE 15. Global Live Biotherapeutic Products & Microbiome CDMO Service Market Size, by Project Phase, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 16. Global Live Biotherapeutic Products & Microbiome CDMO Service Market Size, by End User, 2025 vs 2032 (%)
  • FIGURE 17. Global Live Biotherapeutic Products & Microbiome CDMO Service Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 18. Global Live Biotherapeutic Products & Microbiome CDMO Service Market Size, by Region, 2025 vs 2032 (%)
  • FIGURE 19. Global Live Biotherapeutic Products & Microbiome CDMO Service Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 20. Global Live Biotherapeutic Products & Microbiome CDMO Service Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 21. Global Live Biotherapeutic Products & Microbiome CDMO Service Market Size, by Country, 2025 vs 2032 (%)
  • FIGURE 22. Global Live Biotherapeutic Products & Microbiome CDMO Service Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 23. Global Live Biotherapeutic Products & Microbiome CDMO Service Market Share, by Key Player, 2025

LIST OF TABLES

  • TABLE 1. Global Live Biotherapeutic Products & Microbiome CDMO Service Market Segmentation & Coverage
  • TABLE 2. Global Live Biotherapeutic Products & Microbiome CDMO Service Market Size, 2017-2032 (USD Million)
  • TABLE 3. Global Live Biotherapeutic Products & Microbiome CDMO Service Market Size, by Service Type, 2017-2032 (USD Million)
  • TABLE 4. Global Analytical Services Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 5. Global Analytical Services Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 6. Global Analytical Services Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 7. Global Bioanalytical Testing Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 8. Global Bioanalytical Testing Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 9. Global Bioanalytical Testing Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 10. Global Microbiological Testing Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 11. Global Microbiological Testing Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 12. Global Microbiological Testing Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 13. Global Clinical Development Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 14. Global Clinical Development Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 15. Global Clinical Development Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 16. Global Phase I Trials Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 17. Global Phase I Trials Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 18. Global Phase I Trials Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 19. Global Phase II Trials Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 20. Global Phase II Trials Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 21. Global Phase II Trials Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 22. Global Phase III Trials Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 23. Global Phase III Trials Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 24. Global Phase III Trials Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 25. Global Commercial Manufacturing Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 26. Global Commercial Manufacturing Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 27. Global Commercial Manufacturing Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 28. Global Downstream Processing Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 29. Global Downstream Processing Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 30. Global Downstream Processing Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 31. Global Fill Finish Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 32. Global Fill Finish Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 33. Global Fill Finish Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 34. Global Upstream Processing Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 35. Global Upstream Processing Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 36. Global Upstream Processing Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 37. Global Live Biotherapeutic Products & Microbiome CDMO Service Market Size, by Technology Platform, 2017-2032 (USD Million)
  • TABLE 38. Global Encapsulation Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 39. Global Encapsulation Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 40. Global Encapsulation Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 41. Global Microencapsulation Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 42. Global Microencapsulation Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 43. Global Microencapsulation Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 44. Global Nanoencapsulation Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 45. Global Nanoencapsulation Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 46. Global Nanoencapsulation Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 47. Global Fermentation Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 48. Global Fermentation Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 49. Global Fermentation Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 50. Global Aerobic Fermentation Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 51. Global Aerobic Fermentation Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 52. Global Aerobic Fermentation Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 53. Global Anaerobic Fermentation Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 54. Global Anaerobic Fermentation Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 55. Global Anaerobic Fermentation Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 56. Global Genetic Engineering Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 57. Global Genetic Engineering Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 58. Global Genetic Engineering Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 59. Global CRISPR Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 60. Global CRISPR Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 61. Global CRISPR Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 62. Global Plasmid Engineering Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 63. Global Plasmid Engineering Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 64. Global Plasmid Engineering Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 65. Global Lyophilization Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 66. Global Lyophilization Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 67. Global Lyophilization Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 68. Global Bulk Lyophilization Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 69. Global Bulk Lyophilization Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 70. Global Bulk Lyophilization Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 71. Global Vial Lyophilization Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 72. Global Vial Lyophilization Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 73. Global Vial Lyophilization Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 74. Global Live Biotherapeutic Products & Microbiome CDMO Service Market Size, by Therapeutic Area, 2017-2032 (USD Million)
  • TABLE 75. Global Gastrointestinal Disorders Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 76. Global Gastrointestinal Disorders Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 77. Global Gastrointestinal Disorders Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 78. Global Infectious Diseases Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 79. Global Infectious Diseases Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 80. Global Infectious Diseases Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 81. Global Bacterial Infections Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 82. Global Bacterial Infections Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 83. Global Bacterial Infections Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 84. Global Viral Infections Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 85. Global Viral Infections Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 86. Global Viral Infections Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 87. Global Metabolic Disorders Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 88. Global Metabolic Disorders Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 89. Global Metabolic Disorders Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 90. Global Oncology Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 91. Global Oncology Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 92. Global Oncology Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 93. Global Live Biotherapeutic Products & Microbiome CDMO Service Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 94. Global Injectable Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 95. Global Injectable Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 96. Global Injectable Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 97. Global Intravenous Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 98. Global Intravenous Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 99. Global Intravenous Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 100. Global Subcutaneous Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 101. Global Subcutaneous Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 102. Global Subcutaneous Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 103. Global Oral Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 104. Global Oral Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 105. Global Oral Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 106. Global Capsule Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 107. Global Capsule Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 108. Global Capsule Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 109. Global Tablet Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 110. Global Tablet Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 111. Global Tablet Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 112. Global Rectal Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 113. Global Rectal Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 114. Global Rectal Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 115. Global Topical Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 116. Global Topical Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 117. Global Topical Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 118. Global Live Biotherapeutic Products & Microbiome CDMO Service Market Size, by Project Phase, 2017-2032 (USD Million)
  • TABLE 119. Global Commercial Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 120. Global Commercial Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 121. Global Commercial Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 122. Global Phase I Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 123. Global Phase I Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 124. Global Phase I Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 125. Global Phase II Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 126. Global Phase II Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 127. Global Phase II Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 128. Global Phase III Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 129. Global Phase III Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 130. Global Phase III Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 131. Global Preclinical Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 132. Global Preclinical Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 133. Global Preclinical Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 134. Global Live Biotherapeutic Products & Microbiome CDMO Service Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 135. Global Contract Research Organizations Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 136. Global Contract Research Organizations Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 137. Global Contract Research Organizations Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 138. Global Pharmaceutical Companies Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 139. Global Pharmaceutical Companies Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 140. Global Pharmaceutical Companies Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 141. Global Research Institutes Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 142. Global Research Institutes Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 143. Global Research Institutes Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 144. Global Live Biotherapeutic Products & Microbiome CDMO Service Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 145. Asia-Pacific Live Biotherapeutic Products & Microbiome CDMO Service Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 146. Asia-Pacific Live Biotherapeutic Products & Microbiome CDMO Service Market Size, by Service Type, 2017-2032 (USD Million)
  • TABLE 147. Asia-Pacific Live Biotherapeutic Products & Microbiome CDMO Service Market Size, by Analytical Services, 2017-2032 (USD Million)
  • TABLE 148. Asia-Pacific Live Biotherapeutic Products & Microbiome CDMO Service Market Size, by Clinical Development, 2017-2032 (USD Million)
  • TABLE 149. Asia-Pacific Live Biotherapeutic Products & Microbiome CDMO Service Market Size, by Commercial Manufacturing, 2017-2032 (USD Million)
  • TABLE 150. Asia-Pacific Live Biotherapeutic Products & Microbiome CDMO Service Market Size, by Technology Platform, 2017-2032 (USD Million)
  • TABLE 151. Asia-Pacific Live Biotherapeutic Products & Microbiome CDMO Service Market Size, by Encapsulation, 2017-2032 (USD Million)
  • TABLE 152. Asia-Pacific Live Biotherapeutic Products & Microbiome CDMO Service Market Size, by Fermentation, 2017-2032 (USD Million)
  • TABLE 153. Asia-Pacific Live Biotherapeutic Products & Microbiome CDMO Service Market Size, by Genetic Engineering, 2017-2032 (USD Million)
  • TABLE 154. Asia-Pacific Live Biotherapeutic Products & Microbiome CDMO Service Market Size, by Lyophilization, 2017-2032 (USD Million)
  • TABLE 155. Asia-Pacific Live Biotherapeutic Products & Microbiome CDMO Service Market Size, by Therapeutic Area, 2017-2032 (USD Million)
  • TABLE 156. Asia-Pacific Live Biotherapeutic Products & Microbiome CDMO Service Market Size, by Infectious Diseases, 2017-2032 (USD Million)
  • TABLE 157. Asia-Pacific Live Biotherapeutic Products & Microbiome CDMO Service Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 158. Asia-Pacific Live Biotherapeutic Products & Microbiome CDMO Service Market Size, by Injectable, 2017-2032 (USD Million)
  • TABLE 159. Asia-Pacific Live Biotherapeutic Products & Microbiome CDMO Service Market Size, by Oral, 2017-2032 (USD Million)
  • TABLE 160. Asia-Pacific Live Biotherapeutic Products & Microbiome CDMO Service Market Size, by Project Phase, 2017-2032 (USD Million)
  • TABLE 161. Asia-Pacific Live Biotherapeutic Products & Microbiome CDMO Service Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 162. North America Live Biotherapeutic Products & Microbiome CDMO Service Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 163. North America Live Biotherapeutic Products & Microbiome CDMO Service Market Size, by Service Type, 2017-2032 (USD Million)
  • TABLE 164. North America Live Biotherapeutic Products & Microbiome CDMO Service Market Size, by Analytical Services, 2017-2032 (USD Million)
  • TABLE 165. North America Live Biotherapeutic Products & Microbiome CDMO Service Market Size, by Clinical Development, 2017-2032 (USD Million)
  • TABLE 166. North America Live Biotherapeutic Products & Microbiome CDMO Service Market Size, by Commercial Manufacturing, 2017-2032 (USD Million)
  • TABLE 167. North America Live Biotherapeutic Products & Microbiome CDMO Service Market Size, by Technology Platform, 2017-2032 (USD Million)
  • TABLE 168. North America Live Biotherapeutic Products & Microbiome CDMO Service Market Size, by Encapsulation, 2017-2032 (USD Million)
  • TABLE 169. North America Live Biotherapeutic Products & Microbiome CDMO Service Market Size, by Fermentation, 2017-2032 (USD Million)
  • TABLE 170. North America Live Biotherapeutic Products & Microbiome CDMO Service Market Size, by Genetic Engineering, 2017-2032 (USD Million)
  • TABLE 171. North America Live Biotherapeutic Products & Microbiome CDMO Service Market Size, by Lyophilization, 2017-2032 (USD Million)
  • TABLE 172. North America Live Biotherapeutic Products & Microbiome CDMO Service Market Size, by Therapeutic Area, 2017-2032 (USD Million)
  • TABLE 173. North America Live Biotherapeutic Products & Microbiome CDMO Service Market Size, by Infectious Diseases, 2017-2032 (USD Million)
  • TABLE 174. North America Live Biotherapeutic Products & Microbiome CDMO Service Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 175. North America Live Biotherapeutic Products & Microbiome CDMO Service Market Size, by Injectable, 2017-2032 (USD Million)
  • TABLE 176. North America Live Biotherapeutic Products & Microbiome CDMO Service Market Size, by Oral, 2017-2032 (USD Million)
  • TABLE 177. North America Live Biotherapeutic Products & Microbiome CDMO Service Market Size, by Project Phase, 2017-2032 (USD Million)
  • TABLE 178. North America Live Biotherapeutic Products & Microbiome CDMO Service Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 179. Latin America Live Biotherapeutic Products & Microbiome CDMO Service Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 180. Latin America Live Biotherapeutic Products & Microbiome CDMO Service Market Size, by Service Type, 2017-2032 (USD Million)
  • TABLE 181. Latin America Live Biotherapeutic Products & Microbiome CDMO Service Market Size, by Analytical Services, 2017-2032 (USD Million)
  • TABLE 182. Latin America Live Biotherapeutic Products & Microbiome CDMO Service Market Size, by Clinical Development, 2017-2032 (USD Million)
  • TABLE 183. Latin America Live Biotherapeutic Products & Microbiome CDMO Service Market Size, by Commercial Manufacturing, 2017-2032 (USD Million)
  • TABLE 184. Latin America Live Biotherapeutic Products & Microbiome CDMO Service Market Size, by Technology Platform, 2017-2032 (USD Million)
  • TABLE 185. Latin America Live Biotherapeutic Products & Microbiome CDMO Service Market Size, by Encapsulation, 2017-2032 (USD Million)
  • TABLE 186. Latin America Live Biotherapeutic Products & Microbiome CDMO Service Market Size, by Fermentation, 2017-2032 (USD Million)
  • TABLE 187. Latin America Live Biotherapeutic Products & Microbiome CDMO Service Market Size, by Genetic Engineering, 2017-2032 (USD Million)
  • TABLE 188. Latin America Live Biotherapeutic Products & Microbiome CDMO Service Market Size, by Lyophilization, 2017-2032 (USD Million)
  • TABLE 189. Latin America Live Biotherapeutic Products & Microbiome CDMO Service Market Size, by Therapeutic Area, 2017-2032 (USD Million)
  • TABLE 190. Latin America Live Biotherapeutic Products & Microbiome CDMO Service Market Size, by Infectious Diseases, 2017-2032 (USD Million)
  • TABLE 191. Latin America Live Biotherapeutic Products & Microbiome CDMO Service Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 192. Latin America Live Biotherapeutic Products & Microbiome CDMO Service Market Size, by Injectable, 2017-2032 (USD Million)
  • TABLE 193. Latin America Live Biotherapeutic Products & Microbiome CDMO Service Market Size, by Oral, 2017-2032 (USD Million)
  • TABLE 194. Latin America Live Biotherapeutic Products & Microbiome CDMO Service Market Size, by Project Phase, 2017-2032 (USD Million)
  • TABLE 195. Latin America Live Biotherapeutic Products & Microbiome CDMO Service Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 196. Europe Live Biotherapeutic Products & Microbiome CDMO Service Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 197. Europe Live Biotherapeutic Products & Microbiome CDMO Service Market Size, by Service Type, 2017-2032 (USD Million)
  • TABLE 198. Europe Live Biotherapeutic Products & Microbiome CDMO Service Market Size, by Analytical Services, 2017-2032 (USD Million)
  • TABLE 199. Europe Live Biotherapeutic Products & Microbiome CDMO Service Market Size, by Clinical Development, 2017-2032 (USD Million)
  • TABLE 200. Europe Live Biotherapeutic Products & Microbiome CDMO Service Market Size, by Commercial Manufacturing, 2017-2032 (USD Million)
  • TABLE 201. Europe Live Biotherapeutic Products & Microbiome CDMO Service Market Size, by Technology Platform, 2017-2032 (USD Million)
  • TABLE 202. Europe Live Biotherapeutic Products & Microbiome CDMO Service Market Size, by Encapsulation, 2017-2032 (USD Million)
  • TABLE 203. Europe Live Biotherapeutic Products & Microbiome CDMO Service Market Size, by Fermentation, 2017-2032 (USD Million)
  • TABLE 204. Europe Live Biotherapeutic Products & Microbiome CDMO Service Market Size, by Genetic Engineering, 2017-2032 (USD Million)
  • TABLE 205. Europe Live Biotherapeutic Products & Microbiome CDMO Service Market Size, by Lyophilization, 2017-2032 (USD Million)
  • TABLE 206. Europe Live Biotherapeutic Products & Microbiome CDMO Service Market Size, by Therapeutic Area, 2017-2032 (USD Million)
  • TABLE 207. Europe Live Biotherapeutic Products & Microbiome CDMO Service Market Size, by Infectious Diseases, 2017-2032 (USD Million)
  • TABLE 208. Europe Live Biotherapeutic Products & Microbiome CDMO Service Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 209. Europe Live Biotherapeutic Products & Microbiome CDMO Service Market Size, by Injectable, 2017-2032 (USD Million)
  • TABLE 210. Europe Live Biotherapeutic Products & Microbiome CDMO Service Market Size, by Oral, 2017-2032 (USD Million)
  • TABLE 211. Europe Live Biotherapeutic Products & Microbiome CDMO Service Market Size, by Project Phase, 2017-2032 (USD Million)
  • TABLE 212. Europe Live Biotherapeutic Products & Microbiome CDMO Service Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 213. Middle East Live Biotherapeutic Products & Microbiome CDMO Service Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 214. Middle East Live Biotherapeutic Products & Microbiome CDMO Service Market Size, by Service Type, 2017-2032 (USD Million)
  • TABLE 215. Middle East Live Biotherapeutic Products & Microbiome CDMO Service Market Size, by Analytical Services, 2017-2032 (USD Million)
  • TABLE 216. Middle East Live Biotherapeutic Products & Microbiome CDMO Service Market Size, by Clinical Development, 2017-2032 (USD Million)
  • TABLE 217. Middle East Live Biotherapeutic Products & Microbiome CDMO Service Market Size, by Commercial Manufacturing, 2017-2032 (USD Million)
  • TABLE 218. Middle East Live Biotherapeutic Products & Microbiome CDMO Service Market Size, by Technology Platform, 2017-2032 (USD Million)
  • TABLE 219. Middle East Live Biotherapeutic Products & Microbiome CDMO Service Market Size, by Encapsulation, 2017-2032 (USD Million)
  • TABLE 220. Middle East Live Biotherapeutic Products & Microbiome CDMO Service Market Size, by Fermentation, 2017-2032 (USD Million)
  • TABLE 221. Middle East Live Biotherapeutic Products & Microbiome CDMO Service Market Size, by Genetic Engineering, 2017-2032 (USD Million)
  • TABLE 222. Middle East Live Biotherapeutic Products & Microbiome CDMO Service Market Size, by Lyophilization, 2017-2032 (USD Million)
  • TABLE 223. Middle East Live Biotherapeutic Products & Microbiome CDMO Service Market Size, by Therapeutic Area, 2017-2032 (USD Million)
  • TABLE 224. Middle East Live Biotherapeutic Products & Microbiome CDMO Service Market Size, by Infectious Diseases, 2017-2032 (USD Million)
  • TABLE 225. Middle East Live Biotherapeutic Products & Microbiome CDMO Service Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 226. Middle East Live Biotherapeutic Products & Microbiome CDMO Service Market Size, by Injectable, 2017-2032 (USD Million)
  • TABLE 227. Middle East Live Biotherapeutic Products & Microbiome CDMO Service Market Size, by Oral, 2017-2032 (USD Million)
  • TABLE 228. Middle East Live Biotherapeutic Products & Microbiome CDMO Service Market Size, by Project Phase, 2017-2032 (USD Million)
  • TABLE 229. Middle East Live Biotherapeutic Products & Microbiome CDMO Service Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 230. Africa Live Biotherapeutic Products & Microbiome CDMO Service Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 231. Africa Live Biotherapeutic Products & Microbiome CDMO Service Market Size, by Service Type, 2017-2032 (USD Million)
  • TABLE 232. Africa Live Biotherapeutic Products & Microbiome CDMO Service Market Size, by Analytical Services, 2017-2032 (USD Million)
  • TABLE 233. Africa Live Biotherapeutic Products & Microbiome CDMO Service Market Size, by Clinical Development, 2017-2032 (USD Million)
  • TABLE 234. Africa Live Biotherapeutic Products & Microbiome CDMO Service Market Size, by Commercial Manufacturing, 2017-2032 (USD Million)
  • TABLE 235. Africa Live Biotherapeutic Products & Microbiome CDMO Service Market Size, by Technology Platform, 2017-2032 (USD Million)
  • TABLE 236. Africa Live Biotherapeutic Products & Microbiome CDMO Service Market Size, by Encapsulation, 2017-2032 (USD Million)
  • TABLE 237. Africa Live Biotherapeutic Products & Microbiome CDMO Service Market Size, by Fermentation, 2017-2032 (USD Million)
  • TABLE 238. Africa Live Biotherapeutic Products & Microbiome CDMO Service Market Size, by Genetic Engineering, 2017-2032 (USD Million)
  • TABLE 239. Africa Live Biotherapeutic Products & Microbiome CDMO Service Market Size, by Lyophilization, 2017-2032 (USD Million)
  • TABLE 240. Africa Live Biotherapeutic Products & Microbiome CDMO Service Market Size, by Therapeutic Area, 2017-2032 (USD Million)
  • TABLE 241. Africa Live Biotherapeutic Products & Microbiome CDMO Service Market Size, by Infectious Diseases, 2017-2032 (USD Million)
  • TABLE 242. Africa Live Biotherapeutic Products & Microbiome CDMO Service Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 243. Africa Live Biotherapeutic Products & Microbiome CDMO Service Market Size, by Injectable, 2017-2032 (USD Million)
  • TABLE 244. Africa Live Biotherapeutic Products & Microbiome CDMO Service Market Size, by Oral, 2017-2032 (USD Million)
  • TABLE 245. Africa Live Biotherapeutic Products & Microbiome CDMO Service Market Size, by Project Phase, 2017-2032 (USD Million)
  • TABLE 246. Africa Live Biotherapeutic Products & Microbiome CDMO Service Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 247. Global Live Biotherapeutic Products & Microbiome CDMO Service Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 248. ASEAN Live Biotherapeutic Products & Microbiome CDMO Service Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 249. ASEAN Live Biotherapeutic Products & Microbiome CDMO Service Market Size, by Service Type, 2017-2032 (USD Million)
  • TABLE 250. ASEAN Live Biotherapeutic Products & Microbiome CDMO Service Market Size, by Analytical Services, 2017-2032 (USD Million)
  • TABLE 251. ASEAN Live Biotherapeutic Products & Microbiome CDMO Service Market Size, by Clinical Development, 2017-2032 (USD Million)
  • TABLE 252. ASEAN Live Biotherapeutic Products & Microbiome CDMO Service Market Size, by Commercial Manufacturing, 2017-2032 (USD Million)
  • TABLE 253. ASEAN Live Biotherapeutic Products & Microbiome CDMO Service Market Size, by Technology Platform, 2017-2032 (USD Million)
  • TABLE 254. ASEAN Live Biotherapeutic Products & Microbiome CDMO Service Market Size, by Encapsulation, 2017-2032 (USD Million)
  • TABLE 255. ASEAN Live Biotherapeutic Products & Microbiome CDMO Service Market Size, by Fermentation, 2017-2032 (USD Million)
  • TABLE 256. ASEAN Live Biotherapeutic Products & Microbiome CDMO Service Market Size, by Genetic Engineering, 2017-2032 (USD Million)
  • TABLE 257. ASEAN Live Biotherapeutic Products & Microbiome CDMO Service Market Size, by Lyophilization, 2017-2032 (USD Million)
  • TABLE 258. ASEAN Live Biotherapeutic Products & Microbiome CDMO Service Market Size, by Therapeutic Area, 2017-2032 (USD Million)
  • TABLE 259. ASEAN Live Biotherapeutic Products & Microbiome CDMO Service Market Size, by Infectious Diseases, 2017-2032 (USD Million)
  • TABLE 260. ASEAN Live Biotherapeutic Products & Microbiome CDMO Service Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 261. ASEAN Live Biotherapeutic Products & Microbiome CDMO Service Market Size, by Injectable, 2017-2032 (USD Million)
  • TABLE 262. ASEAN Live Biotherapeutic Products & Microbiome CDMO Service Market Size, by Oral, 2017-2032 (USD Million)
  • TABLE 263. ASEAN Live Biotherapeutic Products & Microbiome CDMO Service Market Size, by Project Phase, 2017-2032 (USD Million)
  • TABLE 264. ASEAN Live Biotherapeutic Products & Microbiome CDMO Service Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 265. GCC Live Biotherapeutic Products & Microbiome CDMO Service Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 266. GCC Live Biotherapeutic Products & Microbiome CDMO Service Market Size, by Service Type, 2017-2032 (USD Million)
  • TABLE 267. GCC Live Biotherapeutic Products & Microbiome CDMO Service Market Size, by Analytical Services, 2017-2032 (USD Million)
  • TABLE 268. GCC Live Biotherapeutic Products & Microbiome CDMO Service Market Size, by Clinical Development, 2017-2032 (USD Million)
  • TABLE 269. GCC Live Biotherapeutic Products & Microbiome CDMO Service Market Size, by Commercial Manufacturing, 2017-2032 (USD Million)
  • TABLE 270. GCC Live Biotherapeutic Products & Microbiome CDMO Service Market Size, by Technology Platform, 2017-2032 (USD Million)
  • TABLE 271. GCC Live Biotherapeutic Products & Microbiome CDMO Service Market Size, by Encapsulation, 2017-2032 (USD Million)
  • TABLE 272. GCC Live Biotherapeutic Products & Microbiome CDMO Service Market Size, by Fermentation, 2017-2032 (USD Million)
  • TABLE 273. GCC Live Biotherapeutic Products & Microbiome CDMO Service Market Size, by Genetic Engineering, 2017-2032 (USD Million)
  • TABLE 274. GCC Live Biotherapeutic Products & Microbiome CDMO Service Market Size, by Lyophilization, 2017-2032 (USD Million)
  • TABLE 275. GCC Live Biotherapeutic Products & Microbiome CDMO Service Market Size, by Therapeutic Area, 2017-2032 (USD Million)
  • TABLE 276. GCC Live Biotherapeutic Products & Microbiome CDMO Service Market Size, by Infectious Diseases, 2017-2032 (USD Million)
  • TABLE 277. GCC Live Biotherapeutic Products & Microbiome CDMO Service Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 278. GCC Live Biotherapeutic Products & Microbiome CDMO Service Market Size, by Injectable, 2017-2032 (USD Million)
  • TABLE 279. GCC Live Biotherapeutic Products & Microbiome CDMO Service Market Size, by Oral, 2017-2032 (USD Million)
  • TABLE 280. GCC Live Biotherapeutic Products & Microbiome CDMO Service Market Size, by Project Phase, 2017-2032 (USD Million)
  • TABLE 281. GCC Live Biotherapeutic Products & Microbiome CDMO Service Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 282. European Union Live Biotherapeutic Products & Microbiome CDMO Service Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 283. European Union Live Biotherapeutic Products & Microbiome CDMO Service Market Size, by Service Type, 2017-2032 (USD Million)
  • TABLE 284. European Union Live Biotherapeutic Products & Microbiome CDMO Service Market Size, by Analytical Services, 2017-2032 (USD Million)
  • TABLE 285. European Union Live Biotherapeutic Products & Microbiome CDMO Service Market Size, by Clinical Development, 2017-2032 (USD Million)
  • TABLE 286. European Union Live Biotherapeutic Products & Microbiome CDMO Service Market Size, by Commercial Manufacturing, 2017-2032 (USD Million)
  • TABLE 287. European Union Live Biotherapeutic Products & Microbiome CDMO Service Market Size, by Technology Platform, 2017-2032 (USD Million)
  • TABLE 288. European Union Live Biotherapeutic Products & Microbiome CDMO Service Market Size, by Encapsulation, 2017-2032 (USD Million)
  • TABLE 289. European Union Live Biotherapeutic Products & Microbiome CDMO Service Market Size, by Fermentation, 2017-2032 (USD Million)
  • TABLE 290. European Union Live Biotherapeutic Products & Microbiome CDMO Service Market Size, by Genetic Engineering, 2017-2032 (USD Million)
  • TABLE 291. European Union Live Biotherapeutic Products & Microbiome CDMO Service Market Size, by Lyophilization, 2017-2032 (USD Million)
  • TABLE 292. European Union Live Biotherapeutic Products & Microbiome CDMO Service Market Size, by Therapeutic Area, 2017-2032 (USD Million)
  • TABLE 293. European Union Live Biotherapeutic Products & Microbiome CDMO Service Market Size, by Infectious Diseases, 2017-2032 (USD Million)
  • TABLE 294. European Union Live Biotherapeutic Products & Microbiome CDMO Service Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 295. European Union Live Biotherapeutic Products & Microbiome CDMO Service Market Size, by Injectable, 2017-2032 (USD Million)
  • TABLE 296. European Union Live Biotherapeutic Products & Microbiome CDMO Service Market Size, by Oral, 2017-2032 (USD Million)
  • TABLE 297. European Union Live Biotherapeutic Products & Microbiome CDMO Service Market Size, by Project Phase, 2017-2032 (USD Million)
  • TABLE 298. European Union Live Biotherapeutic Products & Microbiome CDMO Service Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 299. BRICS Live Biotherapeutic Products & Microbiome CDMO Service Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 300. BRICS Live Biotherapeutic Products & Microbio